Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (33)

I-10John C Lukas

Order in patch absorption rates?

Wednesday 10:30-12:00

I-18Dimitris Maris

Asymptotic Analysis on a TMDD model: Control of the process

Wednesday 10:30-12:00

I-21Nicola Melillo

Multiscale mechanistic models in Systems Pharmacology: development of a model describing Atorvastatin pharmacokinetics through integration of metabolic network in Physiologically Based Pharmacokinetic models.

Wednesday 10:30-12:00

I-25

Application of a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat to improve dosing regimens in adults

Wednesday 10:30-12:00

I-59Christer Rimmler

Development of a PBPK model to predict the pharmacokinetics of cefuroxime during surgery

Wednesday 10:30-12:00

I-61Amin Rostami

Predicting diclofenac systemic and synovial fluid concentrations after dermal application using the Multi-Phase Multi-Layer MechDermA PBPK model

Wednesday 10:30-12:00

II-11Mahendra Shukla

Population Pharmacokinetic-Pharmacodynamic modeling of furosemide for anti-hypertensive effect

Wednesday 15:10-16:30

II-15Konstantina Soulele

Population pharmacokinetic analysis of inhaled budesonide in asthma patients

Wednesday 15:10-16:30

II-26Donato Teutonico

Development of a PBPK model to describe late colonic absorption after oral administration

Wednesday 15:10-16:30

II-32Periklis Tsiros

Bayesian Whole Body Population Physiologically Based Pharmacokinetic Approach for Characterization of Interindividual Variability of Diazepam

Wednesday 15:10-16:30

II-34Denise Feick

Physiologically-Based Pharmacokinetic (PBPK) Modeling of the CYP2C8 Substrate Pioglitazone

Wednesday 15:10-16:30

II-58Jan-Georg Wojtyniak

Physiologically-based Pharmacokinetic (PBPK) Modeling of Simvastatin Drug-Drug Interactions with Rifampin, Clarithromycin and Drug-Gene Interaction with ABCG2

Wednesday 15:10-16:30

II-67Zakaria Zaril

A Mechanistic Pharmacokinetic Approach to the Development of Predictive Models in HIV-malaria co-infection.

Wednesday 15:10-16:30

III-01Elin Boger

Drug targeting in pulmonary sub-epithelial compartments predicted through systems pharmacology modelling

Thursday 09:50-11:20

III-03Elvira Erhardt

Comparison of pharmacokinetic parameters estimated by the experimental R package ‘nlmixr’ and MONOLIX

Thursday 09:50-11:20

III-11Iain Gardner

A Whole body Physiologically based Pharmacokinetic Model for Antibody drug conjugates – model development and validation in rat

Thursday 09:50-11:20

III-21Silvia Grandoni

Evaluation of a minimal WB-PBPK platform supporting different routes of administration

Thursday 09:50-11:20

III-23Benjamin Guiastrennec

Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in human

Thursday 09:50-11:20

III-28Nina Hanke

Physiologically-based pharmacokinetic (PBPK) modeling of alfentanil as a CYP3A4 victim drug

Thursday 09:50-11:20

III-32Eleanor Howgate

Sensitivity analysis of P-glycoprotein Ki values in dynamic DDI predictions

Thursday 09:50-11:20

III-35Ibrahim Ince

Extension of a pregnancy physiologically-based pharmacokinetic model for renally cleared drugs to the postpartum period

Thursday 09:50-11:20

III-37Masoud Jamei

Virtual Bioequivalence Assessment of Two Tramadol Formulations using the Advanced Dissolution Absorption and Metabolism (ADAM) model via Simcyp R Package

Thursday 09:50-11:20

III-40Jihyun Jeon

Pharmacokinetic modeling of Donepezil after transdermal administration in rat

Thursday 09:50-11:20

III-46Vangelis Karalis

On the population pharmacokinetics and the enterohepatic recirculation of inhaled formoterol in asthma patients

Thursday 09:50-11:20

III-65Jong Bong Lee

In silico modelling of chylomicron association to predict lymphatic absorption of small molecules

Thursday 09:50-11:20

IV-01Khaled Abduljalil

Application of Physiologically-Based Pharmacokinetic model To Predict Tramadol Concentration in human Milk

Thursday 14:45-16:15

IV-10Hyun-moon Back

Development of a Semi-mechanistic absorption model for explaining effect of food on itraconazole

Thursday 14:45-16:15

IV-12Pavel Balazki

Physiologically-based Pharmacokinetics/Pharmacodynamics model of Dapagliflozin, an oral SGLT2 inhibitor

Thursday 14:45-16:15

IV-27Jantine Brussee

Distinguishing between first-pass and systemic CYP3A-mediated metabolism of midazolam in preterm neonates using physiologically-based pharmacokinetic modelling

Thursday 14:45-16:15

IV-33Letizia Carrara

Which data are necessary to build a WB-PBPK model that accurately predicts exposure in the lung? A case study using Ethambutol for tuberculosis treatment

Thursday 14:45-16:15

IV-41Manoranjenni Chetty

Prediction of the pharmacokinetics of renally excreted antiretrovirals in older patients, using physiologically based pharmacokinetic (PBPK) modelling.

Thursday 14:45-16:15

IV-51André Dallmann

Physiologically-based pharmacokinetic modeling of drugs metabolized via several CYP enzymes in populations of pregnant women

Thursday 14:45-16:15

IV-54Mailys De Sousa Mendes

Predicting human foetal exposure using physiologically based pharmacokinetic models

Thursday 14:45-16:15